Merck Enters Into Exclusive Global License Agreement With Scibrunch Therapeutics For SPR2015, An Investigational Oral Kras G12d (On) Inhibitor (Designed To Block The Kras G12D Gene Mutation That Causes Tumours To Grow In Cancers Like Pancreatic And Colorectal Cancer)

Deal Includes $400 Mln Upfront, Total Potential Value $2.13 Bln; Deal Closed